Authors
Jinxiao Li, Keke Jiang, Shuhan Wang, Yuju Cai, Luorui Shang, Fangyuan Zhou, Yuqing Wang, Jianghua Huang, Shan Hu, Qian Yan, Shenglan Yang
Published in
Frontiers in pharmacology. Volume 17. Pages 1813778. Epub Aug 14, 2026.
Abstract
Colorectal cancer (CRC) is one of the most common gastrointestinal tumors with elevated prevalence and high mortality rates, posing a serious threat to human health. As a commonly used classic prescription in the clinical treatment of CRC, Yi-Yi-Fu-Zi-Bai-Jiang-San (YYFZBJS), which is composed of Coix lacryma-jobi L., Aconitum carmichaelii Debeaux, and Patrinia scabiosifolia Fisch. ex Trev., exerts anti-CRC effects by regulating inflammation-cancer transformation, alleviating oxidative stress, restoring gut microbiota balance, inhibiting CRC cell proliferation, promoting apoptosis, regulating autophagy, suppressing tumor angiogenesis. It demonstrates multi-targeted anti-CRC potential and holds promising clinical value as a chemotherapy adjuvant. However, the molecular mechanisms underlying its multi-target anti-CRC effects remain incompletely elucidated and require comprehensive synthesis. This review summarizes the research progress of YYFZBJS in recent years in the field of CRC. It will provide theoretical basis and ideas for further investigation of the role of YYFZBJS in anti-CRC, with the ultimate goal of benefiting the clinical practice.
PMID:
42666771
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0